Catalyst Pharmaceuticals (CPRX) Other Operating Expenses (2019 - 2026)

Catalyst Pharmaceuticals has reported Other Operating Expenses for 8 years, with the latest figure at $24.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 11.29% year-over-year to $24.2 million; the trailing twelve-month figure through Mar 2026 stood at $121.7 million (up 9.01% YoY), and the FY2025 full-year result was $124.8 million, up 17.44% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $24.2 million, down from $35.5 million in the prior quarter.
• The five-year high for Other Operating Expenses was $35.5 million in Q4 2025, with the low at $5.9 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $22.1 million across 5 years, with a median of $24.2 million in 2026.
• Annual changes were most pronounced in 2023 — Other Operating Expenses soared 179.75% — and 2026, when it fell 11.29%.
• Catalyst Pharmaceuticals' Other Operating Expenses stood at $11.8 million in 2022, then surged by 111.19% to $24.9 million in 2023, then advanced by 24.61% to $31.0 million in 2024, then increased by 14.69% to $35.5 million in 2025, then sank by 31.97% to $24.2 million in 2026.
• The last three Other Operating Expenses figures came in at $24.2 million (Q1 2026), $35.5 million (Q4 2025), and $32.0 million (Q3 2025), per Business Quant data.